PMID- 24011633
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20220408
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 82
IP  - 2
DP  - 2013 Nov
TI  - Genetic alterations defining NSCLC subtypes and their therapeutic implications.
PG  - 179-89
LID - S0169-5002(13)00378-4 [pii]
LID - 10.1016/j.lungcan.2013.07.025 [doi]
AB  - Lung cancer is the leading cause of cancer death worldwide, accounting for more 
      deaths than breast, prostate and colon cancer combined. While treatment decisions 
      are determined primarily by stage, therapeutically non small cell lung cancer 
      (NSCLC) has traditionally been treated as a single disease. However, recent 
      findings have led to the recognition of histology and molecular subtypes as 
      important determinants in treatment selection. Identifying the genetic 
      differences that define these molecular and histological subtypes has the 
      potential to impact treatment and as such is currently the focus of much 
      research. Microarray and genomic sequencing efforts have provided unparalleled 
      insight into the genomes of lung cancer subtypes, specifically adenocarcinoma 
      (AC) and squamous cell carcinoma (SqCC), revealing subtype specific genomic 
      alterations and molecular subtypes as well as differences in cell signaling 
      pathways. In this review, we discuss the recurrent genomic alterations 
      characteristic of AC and SqCC (including molecular subtypes), their therapeutic 
      implications and emerging clinical practices aimed at tailoring treatments based 
      on a tumor's molecular alterations with the hope of improving patient response 
      and survival.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights 
      reserved.
FAU - Pikor, Larissa A
AU  - Pikor LA
AD  - British Columbia Cancer Research Centre, Vancouver, BC, V5Z 1L3, Canada; 
      Department of Integrative Oncology, BC Cancer Research Center, Canada. Electronic 
      address: lpikor@bccrc.ca.
FAU - Ramnarine, Varune R
AU  - Ramnarine VR
FAU - Lam, Stephen
AU  - Lam S
FAU - Lam, Wan L
AU  - Lam WL
LA  - eng
GR  - MOP 86731/Canadian Institutes of Health Research/Canada
GR  - MOP 94867/Canadian Institutes of Health Research/Canada
GR  - MOP-110949/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20130820
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/pathology/therapy
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/metabolism/pathology/*therapy
MH  - Carcinoma, Squamous Cell/genetics/metabolism/pathology/therapy
MH  - Humans
MH  - Lung Neoplasms/*genetics/metabolism/pathology/*therapy
MH  - Molecular Targeted Therapy
MH  - Signal Transduction
OTO - NOTNLM
OT  - Actionable alterations
OT  - Adenocarcinoma
OT  - CNA
OT  - Histological subtypes
OT  - Methylation
OT  - Personalized medicine
OT  - Sequencing
OT  - Squamous cell carcinoma
EDAT- 2013/09/10 06:00
MHDA- 2014/06/10 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/04/22 00:00 [received]
PHST- 2013/07/20 00:00 [revised]
PHST- 2013/07/29 00:00 [accepted]
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - S0169-5002(13)00378-4 [pii]
AID - 10.1016/j.lungcan.2013.07.025 [doi]
PST - ppublish
SO  - Lung Cancer. 2013 Nov;82(2):179-89. doi: 10.1016/j.lungcan.2013.07.025. Epub 2013 
      Aug 20.